← All trials
NCT05212987
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- May 8, 2024
- Completion date
- Oct 12, 2024
- First posted
- Jan 28, 2022
- Last posted
- Jan 28, 2022
- Enrollment
- 43
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fochon Pharmaceuticals, Ltd.Lead sponsor
- Fudan UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.